The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Primary analysis of a phase 2, open-label, multicenter trial of talimogene laherparepvec (T-VEC) plus pembrolizumab (pembro) for the treatment (Tx) of patients (pts) with advanced melanoma (MEL) who progressed on prior anti–PD-1 therapy: MASTERKEY-115.
 
Brian Gastman
Stock and Other Ownership Interests - Castle Biosciences
Consulting or Advisory Role - Castle Biosciences; Quest Imaging
Speakers' Bureau - Castle Biosciences
Research Funding - Alkermes; Instil Bio; Merck; NeoImmuneTech; Quest Imaging
Travel, Accommodations, Expenses - Alkermes
 
Caroline Robert
Stock and Other Ownership Interests - RiboNexus
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; MSD; Novartis; Pfizer; Pierre Fabre; Roche; Sanofi
Research Funding - Novartis (Inst)
 
Helen Gogas
Honoraria - Bristol-Myers Squibb; MSD Oncology; Pierre Fabre; Sanofi/Regeneron
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; MSD Oncology; Pierre Fabre; Sanofi/Regeneron
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); Iovance Biotherapeutics (Inst); MSD Oncology (Inst); Novartis (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; MSD; Pfizer
 
Piotr Rutkowski
Honoraria - Bristol-Myers Squibb; Merck; MSD; Novartis; Pfizer; Pierre Fabre; Roche; Sanofi
Consulting or Advisory Role - Amgen; Blueprint Medicines; Bristol-Myers Squibb; MSD; Novartis; Pierre Fabre
Speakers' Bureau - Novartis; Pfizer; Pierre Fabre
Research Funding - Bristol-Myers Squibb (Inst); Novartis (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Orphan Europe; Pierre Fabre
 
Georgina V. Long
Honoraria - BMS; Pierre Fabre
Consulting or Advisory Role - Agenus; Amgen; Array BioPharma; Boehringer Ingelheim; Bristol-Myers Squibb; Evaxion Biotech; Hexal; Highlight Therapeutics; Merck Sharpe & Dohme; Novartis; OncoSec; Pierre Fabre; Provectus; QBiotics; Regeneron; Skyline Diagnostics
 
Marya F. Chaney
Employment - Merck
Stock and Other Ownership Interests - Merck
Travel, Accommodations, Expenses - Merck
 
Harshada Joshi
Employment - PAREXEL
 
Yu-Lin Lin
Employment - Amgen
Stock and Other Ownership Interests - Amgen
 
Wendy Snyder
Employment - Amgen
Stock and Other Ownership Interests - Amgen
Travel, Accommodations, Expenses - Amgen
 
Jason Alan Chesney
Research Funding - Amgen; Bristol-Myers Squibb; Iovance Biotherapeutics; Replimune
Patents, Royalties, Other Intellectual Property - University of Louisville US Patents